Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Expected to Post Quarterly Sales of $2.01 Million

Equities analysts expect that Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) will report $2.01 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Corbus Pharmaceuticals’ earnings, with estimates ranging from $1.93 million to $2.10 million. Corbus Pharmaceuticals reported sales of $1.93 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 4.1%. The firm is expected to report its next quarterly earnings results on Tuesday, March 10th.

On average, analysts expect that Corbus Pharmaceuticals will report full year sales of $34.73 million for the current year, with estimates ranging from $34.00 million to $35.18 million. For the next fiscal year, analysts expect that the company will post sales of $7.61 million, with estimates ranging from $4.82 million to $10.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that cover Corbus Pharmaceuticals.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.04. The company had revenue of $2.59 million for the quarter, compared to analysts’ expectations of $1.73 million. Corbus Pharmaceuticals had a negative return on equity of 139.91% and a negative net margin of 164.68%.

Several research firms recently commented on CRBP. BidaskClub upgraded Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada reiterated a “buy” rating and issued a $23.00 price target on shares of Corbus Pharmaceuticals in a research note on Sunday, August 11th. Zacks Investment Research cut Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Finally, ValuEngine cut Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. Corbus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $23.71.

Shares of NASDAQ:CRBP traded up $0.08 during trading on Tuesday, hitting $4.59. The company’s stock had a trading volume of 1,208,800 shares, compared to its average volume of 1,013,153. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.56 and a current ratio of 2.56. Corbus Pharmaceuticals has a fifty-two week low of $4.19 and a fifty-two week high of $9.11. The stock’s 50-day moving average price is $5.02 and its two-hundred day moving average price is $6.11. The company has a market capitalization of $329.72 million, a PE ratio of -4.68 and a beta of 1.87.

In other Corbus Pharmaceuticals news, COO Robert Paul Discordia purchased 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $5.86 per share, for a total transaction of $87,900.00. Following the completion of the purchase, the chief operating officer now owns 30,150 shares in the company, valued at approximately $176,679. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders purchased 19,175 shares of company stock worth $112,241. Insiders own 8.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Aperio Group LLC bought a new stake in Corbus Pharmaceuticals in the second quarter valued at about $29,000. WINTON GROUP Ltd bought a new stake in Corbus Pharmaceuticals in the second quarter valued at about $97,000. Parametric Portfolio Associates LLC bought a new stake in Corbus Pharmaceuticals in the second quarter valued at about $123,000. JPMorgan Chase & Co. increased its holdings in Corbus Pharmaceuticals by 56.0% in the second quarter. JPMorgan Chase & Co. now owns 19,272 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 6,922 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in Corbus Pharmaceuticals by 40.5% in the third quarter. California Public Employees Retirement System now owns 28,676 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 8,270 shares during the last quarter. 49.98% of the stock is owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Recommended Story: What can cause a stock to outperform?

Get a free copy of the Zacks research report on Corbus Pharmaceuticals (CRBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.